Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hippocampus | 45 | 2019 | 171 | 7.550 |
Why?
|
| Neurons | 39 | 2019 | 410 | 4.750 |
Why?
|
| Memory | 22 | 2017 | 190 | 3.450 |
Why?
|
| Action Potentials | 33 | 2019 | 178 | 3.220 |
Why?
|
| Models, Neurological | 32 | 2019 | 117 | 3.130 |
Why?
|
| Psychomotor Performance | 12 | 2018 | 99 | 2.140 |
Why?
|
| Nerve Net | 16 | 2019 | 123 | 2.070 |
Why?
|
| Cannabinoids | 10 | 2017 | 41 | 1.930 |
Why?
|
| Memory, Short-Term | 9 | 2018 | 60 | 1.670 |
Why?
|
| Prefrontal Cortex | 8 | 2014 | 71 | 1.610 |
Why?
|
| Animals | 69 | 2019 | 7542 | 1.310 |
Why?
|
| Rats | 39 | 2017 | 1596 | 1.290 |
Why?
|
| Receptor, Cannabinoid, CB1 | 9 | 2015 | 56 | 1.250 |
Why?
|
| Nonlinear Dynamics | 26 | 2019 | 51 | 1.220 |
Why?
|
| CA1 Region, Hippocampal | 16 | 2017 | 26 | 1.200 |
Why?
|
| Electrodes, Implanted | 12 | 2018 | 41 | 1.160 |
Why?
|
| Macaca mulatta | 17 | 2019 | 305 | 1.160 |
Why?
|
| Endocannabinoids | 5 | 2011 | 35 | 1.130 |
Why?
|
| Rats, Long-Evans | 21 | 2017 | 72 | 1.100 |
Why?
|
| CA3 Region, Hippocampal | 14 | 2017 | 15 | 1.090 |
Why?
|
| Behavior, Animal | 13 | 2017 | 250 | 0.790 |
Why?
|
| Cognition | 8 | 2016 | 556 | 0.750 |
Why?
|
| Prostheses and Implants | 4 | 2016 | 42 | 0.700 |
Why?
|
| Learning | 4 | 2013 | 79 | 0.640 |
Why?
|
| Synaptic Transmission | 6 | 2016 | 117 | 0.620 |
Why?
|
| Pyrazoles | 9 | 2015 | 67 | 0.620 |
Why?
|
| Pyramidal Cells | 3 | 2011 | 16 | 0.610 |
Why?
|
| Mental Recall | 1 | 2018 | 51 | 0.610 |
Why?
|
| Neural Pathways | 8 | 2014 | 94 | 0.590 |
Why?
|
| Reward | 2 | 2010 | 64 | 0.570 |
Why?
|
| Male | 37 | 2019 | 19217 | 0.560 |
Why?
|
| Computer Simulation | 14 | 2019 | 220 | 0.560 |
Why?
|
| Benzoxazines | 9 | 2015 | 21 | 0.540 |
Why?
|
| Naphthalenes | 9 | 2015 | 40 | 0.530 |
Why?
|
| Morpholines | 9 | 2015 | 37 | 0.530 |
Why?
|
| Neuronal Plasticity | 3 | 2017 | 80 | 0.500 |
Why?
|
| Piperidines | 9 | 2015 | 118 | 0.500 |
Why?
|
| Journalism | 1 | 2015 | 1 | 0.500 |
Why?
|
| Electric Stimulation | 7 | 2013 | 104 | 0.500 |
Why?
|
| Neurosciences | 1 | 2015 | 11 | 0.490 |
Why?
|
| Glutamic Acid | 2 | 2014 | 47 | 0.440 |
Why?
|
| Ceramics | 1 | 2013 | 4 | 0.430 |
Why?
|
| Memory Disorders | 4 | 2016 | 54 | 0.430 |
Why?
|
| Biofeedback, Psychology | 1 | 2012 | 10 | 0.410 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2017 | 36 | 0.410 |
Why?
|
| Information Storage and Retrieval | 1 | 2012 | 22 | 0.410 |
Why?
|
| Reaction Time | 5 | 2010 | 117 | 0.390 |
Why?
|
| Cortical Synchronization | 1 | 2011 | 3 | 0.390 |
Why?
|
| Cognition Disorders | 4 | 2012 | 385 | 0.380 |
Why?
|
| Behavior | 2 | 2010 | 30 | 0.380 |
Why?
|
| Sleep Deprivation | 2 | 2007 | 9 | 0.370 |
Why?
|
| Cell Movement | 1 | 2010 | 169 | 0.340 |
Why?
|
| Neurophysiology | 1 | 2009 | 10 | 0.340 |
Why?
|
| Microelectrodes | 4 | 2016 | 16 | 0.320 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2019 | 36 | 0.320 |
Why?
|
| Neural Inhibition | 3 | 2017 | 28 | 0.310 |
Why?
|
| Serial Learning | 1 | 2008 | 1 | 0.310 |
Why?
|
| Brain | 7 | 2018 | 951 | 0.310 |
Why?
|
| Sympathomimetics | 1 | 2007 | 4 | 0.310 |
Why?
|
| Neuropeptides | 1 | 2007 | 17 | 0.300 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 73 | 0.300 |
Why?
|
| Electric Stimulation Therapy | 2 | 2018 | 14 | 0.290 |
Why?
|
| Task Performance and Analysis | 5 | 2017 | 53 | 0.290 |
Why?
|
| Receptors, Drug | 3 | 2003 | 13 | 0.290 |
Why?
|
| Deep Brain Stimulation | 4 | 2015 | 49 | 0.280 |
Why?
|
| Brain Injuries | 2 | 2018 | 93 | 0.280 |
Why?
|
| Receptors, Cannabinoid | 5 | 2011 | 25 | 0.280 |
Why?
|
| Signal Processing, Computer-Assisted | 5 | 2014 | 38 | 0.270 |
Why?
|
| Brain Mapping | 4 | 2010 | 178 | 0.270 |
Why?
|
| Prosthesis Design | 5 | 2016 | 97 | 0.270 |
Why?
|
| Electrophysiology | 3 | 2012 | 70 | 0.260 |
Why?
|
| Epilepsy | 2 | 2017 | 82 | 0.250 |
Why?
|
| Cerebral Cortex | 4 | 2011 | 126 | 0.250 |
Why?
|
| Postural Balance | 2 | 2016 | 182 | 0.240 |
Why?
|
| Photic Stimulation | 3 | 2014 | 158 | 0.240 |
Why?
|
| Pattern Recognition, Visual | 1 | 2004 | 11 | 0.230 |
Why?
|
| Cocaine | 4 | 2012 | 256 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 633 | 0.230 |
Why?
|
| Drug Tolerance | 2 | 2003 | 32 | 0.230 |
Why?
|
| Humans | 24 | 2019 | 32114 | 0.220 |
Why?
|
| Pesticides | 1 | 2016 | 199 | 0.220 |
Why?
|
| Lidocaine | 1 | 2003 | 18 | 0.220 |
Why?
|
| Receptors, GABA-A | 1 | 2003 | 32 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 232 | 0.220 |
Why?
|
| Marijuana Abuse | 1 | 2003 | 19 | 0.210 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 94 | 0.210 |
Why?
|
| Motor Activity | 5 | 2015 | 325 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 244 | 0.210 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2003 | 75 | 0.210 |
Why?
|
| Executive Function | 2 | 2013 | 57 | 0.210 |
Why?
|
| Random Allocation | 2 | 2013 | 228 | 0.210 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 128 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 297 | 0.210 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2014 | 743 | 0.200 |
Why?
|
| Analysis of Variance | 4 | 2014 | 464 | 0.190 |
Why?
|
| Arachidonic Acids | 2 | 2011 | 23 | 0.190 |
Why?
|
| Carbamates | 2 | 2011 | 15 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 50 | 0.190 |
Why?
|
| Benzamides | 2 | 2011 | 50 | 0.190 |
Why?
|
| Algorithms | 9 | 2018 | 495 | 0.180 |
Why?
|
| Positron-Emission Tomography | 3 | 2012 | 163 | 0.180 |
Why?
|
| Acetylcholine | 2 | 2010 | 48 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 940 | 0.170 |
Why?
|
| Electrophysiological Phenomena | 3 | 2013 | 27 | 0.160 |
Why?
|
| Calcium | 3 | 2013 | 307 | 0.160 |
Why?
|
| Fibronectins | 1 | 2018 | 36 | 0.160 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 63 | 0.150 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 93 | 0.150 |
Why?
|
| Seizures | 1 | 2018 | 64 | 0.150 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 156 | 0.150 |
Why?
|
| Likelihood Functions | 3 | 2013 | 48 | 0.140 |
Why?
|
| Synapses | 1 | 2017 | 83 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 3 | 2012 | 109 | 0.140 |
Why?
|
| Time Factors | 5 | 2019 | 2151 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 52 | 0.140 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 93 | 0.140 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 245 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2017 | 76 | 0.140 |
Why?
|
| Baclofen | 2 | 2013 | 12 | 0.130 |
Why?
|
| Biological Clocks | 1 | 2015 | 4 | 0.130 |
Why?
|
| Equipment Design | 4 | 2009 | 171 | 0.130 |
Why?
|
| Space Perception | 2 | 2007 | 27 | 0.130 |
Why?
|
| Pattern Recognition, Physiological | 1 | 2014 | 3 | 0.120 |
Why?
|
| Electrodes | 2 | 2013 | 17 | 0.120 |
Why?
|
| Probability Theory | 1 | 2014 | 1 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2015 | 59 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2015 | 71 | 0.120 |
Why?
|
| Glycine | 2 | 2013 | 27 | 0.120 |
Why?
|
| Psychotropic Drugs | 1 | 2014 | 12 | 0.120 |
Why?
|
| Sleep | 1 | 2015 | 92 | 0.120 |
Why?
|
| Neuroprotective Agents | 2 | 2005 | 28 | 0.120 |
Why?
|
| Spatial Behavior | 2 | 2013 | 11 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2015 | 161 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 93 | 0.110 |
Why?
|
| Monte Carlo Method | 3 | 2014 | 18 | 0.110 |
Why?
|
| User-Computer Interface | 2 | 2011 | 51 | 0.110 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2013 | 3 | 0.110 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2013 | 7 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 78 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 101 | 0.100 |
Why?
|
| ROC Curve | 4 | 2014 | 164 | 0.100 |
Why?
|
| Information Theory | 1 | 2011 | 3 | 0.100 |
Why?
|
| Electroencephalography | 3 | 2018 | 73 | 0.100 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 36 | 0.100 |
Why?
|
| Cell Communication | 1 | 2011 | 32 | 0.100 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2011 | 9 | 0.100 |
Why?
|
| Maze Learning | 2 | 2010 | 13 | 0.100 |
Why?
|
| Glycerides | 1 | 2011 | 13 | 0.100 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 19 | 0.100 |
Why?
|
| Injections | 1 | 2011 | 64 | 0.100 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2011 | 2 | 0.100 |
Why?
|
| Second Messenger Systems | 1 | 2011 | 6 | 0.100 |
Why?
|
| Wakefulness | 2 | 2015 | 25 | 0.090 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2011 | 18 | 0.090 |
Why?
|
| Macaca | 1 | 2010 | 27 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2010 | 36 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2011 | 229 | 0.090 |
Why?
|
| Telemetry | 1 | 2009 | 26 | 0.080 |
Why?
|
| Exploratory Behavior | 1 | 2009 | 30 | 0.080 |
Why?
|
| Video Recording | 1 | 2009 | 59 | 0.080 |
Why?
|
| Decision Making | 1 | 2010 | 195 | 0.080 |
Why?
|
| Administration, Intranasal | 1 | 2007 | 31 | 0.080 |
Why?
|
| Discriminant Analysis | 1 | 2007 | 21 | 0.070 |
Why?
|
| Oxazoles | 2 | 2005 | 5 | 0.070 |
Why?
|
| Glucose | 1 | 2007 | 174 | 0.070 |
Why?
|
| Orientation | 1 | 2006 | 24 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 946 | 0.070 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2005 | 4 | 0.070 |
Why?
|
| Biomimetics | 1 | 2005 | 6 | 0.070 |
Why?
|
| Receptors, AMPA | 1 | 2005 | 13 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 684 | 0.060 |
Why?
|
| Nootropic Agents | 1 | 2005 | 12 | 0.060 |
Why?
|
| Ryanodine | 1 | 2005 | 3 | 0.060 |
Why?
|
| Methylmercury Compounds | 1 | 2004 | 4 | 0.060 |
Why?
|
| Cytosol | 1 | 2004 | 25 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2004 | 26 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 35 | 0.060 |
Why?
|
| Hand | 1 | 2004 | 66 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 765 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 898 | 0.060 |
Why?
|
| Marine Toxins | 1 | 2003 | 3 | 0.060 |
Why?
|
| omega-Conotoxin GVIA | 1 | 2003 | 5 | 0.060 |
Why?
|
| Enzyme Activators | 1 | 2003 | 5 | 0.060 |
Why?
|
| Sodium Channel Blockers | 1 | 2003 | 7 | 0.060 |
Why?
|
| Interneurons | 1 | 2003 | 22 | 0.050 |
Why?
|
| GABA Agonists | 1 | 2003 | 2 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2004 | 79 | 0.050 |
Why?
|
| GABA Antagonists | 1 | 2003 | 12 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 48 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 1 | 2003 | 75 | 0.050 |
Why?
|
| Receptors, GABA-B | 1 | 2003 | 13 | 0.050 |
Why?
|
| Models, Theoretical | 3 | 2012 | 137 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 55 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2003 | 59 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 166 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 276 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 130 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1538 | 0.050 |
Why?
|
| Cyclohexanols | 2 | 2015 | 20 | 0.050 |
Why?
|
| Models, Statistical | 3 | 2007 | 175 | 0.050 |
Why?
|
| Dizocilpine Maleate | 2 | 2011 | 7 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2011 | 25 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 582 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 449 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 495 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 81 | 0.040 |
Why?
|
| Adult | 2 | 2016 | 9380 | 0.040 |
Why?
|
| Receptors, GABA | 1 | 2017 | 6 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2010 | 78 | 0.040 |
Why?
|
| Normal Distribution | 2 | 2009 | 12 | 0.040 |
Why?
|
| Vision, Ocular | 1 | 2017 | 33 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2017 | 30 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 101 | 0.040 |
Why?
|
| Computational Biology | 1 | 2017 | 91 | 0.040 |
Why?
|
| Gene Expression | 1 | 2018 | 338 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 120 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 10 | 0.030 |
Why?
|
| Sleep, REM | 1 | 2015 | 6 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 33 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2010 | 1022 | 0.030 |
Why?
|
| Oxotremorine | 1 | 2013 | 3 | 0.030 |
Why?
|
| Resorcinols | 1 | 2013 | 6 | 0.030 |
Why?
|
| Muscarinic Agonists | 1 | 2013 | 6 | 0.030 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2013 | 15 | 0.030 |
Why?
|
| Concept Formation | 1 | 2013 | 3 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2013 | 60 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 767 | 0.030 |
Why?
|
| Aged | 1 | 2016 | 10314 | 0.030 |
Why?
|
| Analog-Digital Conversion | 1 | 2012 | 1 | 0.030 |
Why?
|
| Amplifiers, Electronic | 1 | 2012 | 2 | 0.030 |
Why?
|
| Electronics | 1 | 2012 | 14 | 0.030 |
Why?
|
| Computer Systems | 1 | 2011 | 12 | 0.020 |
Why?
|
| Middle Aged | 1 | 2016 | 11839 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 81 | 0.020 |
Why?
|
| Online Systems | 1 | 2011 | 12 | 0.020 |
Why?
|
| Primates | 1 | 2012 | 108 | 0.020 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2012 | 117 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 3 | 0.020 |
Why?
|
| Phenylcarbamates | 1 | 2010 | 3 | 0.020 |
Why?
|
| Acetylcholinesterase | 1 | 2010 | 18 | 0.020 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 31 | 0.020 |
Why?
|
| Scopolamine | 1 | 2010 | 5 | 0.020 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 10 | 0.020 |
Why?
|
| Feedback, Sensory | 1 | 2010 | 3 | 0.020 |
Why?
|
| Dopamine | 1 | 2012 | 232 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2004 | 682 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2009 | 17 | 0.020 |
Why?
|
| Uncertainty | 1 | 2009 | 10 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 2484 | 0.020 |
Why?
|
| Swimming | 1 | 2007 | 6 | 0.020 |
Why?
|
| Extinction, Psychological | 1 | 2007 | 18 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 45 | 0.020 |
Why?
|
| Microinjections | 1 | 2007 | 35 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 371 | 0.020 |
Why?
|
| Female | 1 | 2016 | 20015 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2006 | 4 | 0.020 |
Why?
|
| Dendrites | 1 | 2006 | 16 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2005 | 42 | 0.020 |
Why?
|
| Macrocyclic Compounds | 1 | 2005 | 1 | 0.020 |
Why?
|
| Thionucleotides | 1 | 2005 | 3 | 0.020 |
Why?
|
| Dantrolene | 1 | 2005 | 2 | 0.020 |
Why?
|
| Estrenes | 1 | 2005 | 2 | 0.020 |
Why?
|
| Okadaic Acid | 1 | 2005 | 4 | 0.020 |
Why?
|
| Pyrrolidinones | 1 | 2005 | 5 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 2005 | 12 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 2005 | 45 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 19 | 0.020 |
Why?
|
| Cell Death | 1 | 2005 | 77 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2005 | 46 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 57 | 0.020 |
Why?
|
| Fetus | 1 | 2005 | 86 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2004 | 20 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 173 | 0.010 |
Why?
|
| Cannabis | 1 | 2004 | 25 | 0.010 |
Why?
|
| Research | 1 | 2004 | 74 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 30 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2002 | 23 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 160 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 834 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 181 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 322 | 0.010 |
Why?
|